The Science Behind Earlier Detection
Discover how the InterceptIQ™ Platform combines advanced molecular diagnostics, β-cell biology, cell-free DNA, and artificial intelligence to generate actionable insight into metabolic disease — before traditional clinical markers become abnormal.
The Clinical Problem
Disease begins long before symptoms.
Type 1 and Type 2 diabetes develop silently for years before HbA1c, fasting glucose, or symptoms appear. By the time a patient is diagnosed, half of β-cell function may already be lost — and complications have begun.
Why Earlier Detection Matters
A continuum where every stage is an opportunity to intervene.
InterceptIQ™ is positioned at the earliest biological stages — where intervention is most effective and disease progression is still reversible.
Molecular Signals
cfDNA, epigenetic, and methylation signatures appear.
Beta Cell Biology
Where metabolic disease begins.
Pancreatic β-cells produce the insulin that keeps blood glucose in balance. In both T1D and T2D, β-cells are silently injured, stressed, and lost long before clinical disease appears.
- Direct evidence of active β-cell injury — not a downstream proxy
- Detects stress before insulin output fails
- Anchored in three decades of peer-reviewed islet biology research
Cell-Free DNA Technology
A molecular fingerprint of tissue injury.
When β-cells are injured, short DNA fragments with tissue-specific methylation patterns are released into the bloodstream. We measure these fragments directly from plasma — a non-invasive readout of β-cell health in real time.
Digital Droplet PCR
Quantifying biology, droplet by droplet.
ddPCR partitions each sample into tens of thousands of nanoliter droplets, enabling absolute quantification of rare molecular signals with unmatched precision and reproducibility.
- 1Plasma inputCell-free DNA extracted from a standard plasma tube.
- 2Droplet partitionSample partitioned into ~20,000 nanoliter droplets.
- 3Targeted amplificationMethylation-specific probes amplify β-cell-derived DNA.
- 4Absolute quantificationDroplet-level counting yields high-sensitivity signal.
Multi-Biomarker Integration
One panel. Complete metabolic picture.
A single blood draw captures autoimmunity, β-cell injury, insulin reserve, and glycemic control — six signals integrated into one clinical assessment.
Artificial Intelligence
Signals become a unified clinical story.
Our models integrate β-cell cfDNA, autoimmune risk, insulin reserve, and glycemic context into a single, weighted Intercept Score™ — calibrated for clinical decision-making and longitudinal monitoring.
The InterceptIQ™ Platform
From sample to clinical action.
Five integrated layers translate a routine blood draw into precise, longitudinal insight — engineered for clinical and research workflows.
Clinical Validation
Grounded in decades of peer-reviewed science.
Our methods are built on more than 30 years of pancreatic islet research and validated through partnerships with leading academic centers, registries, and consortia.
Key Scientific Takeaways
What makes InterceptIQ™ different.
Partner with Kihealth on the next generation of preventative diagnostics.
For clinicians, researchers, and pharmaceutical partners ready to detect disease at its earliest biological stage.